Answers are grounded in this paper and cite their sources.
A systematic, structured screening programme is an integral part of modern diabetes care. The remit, however, remained firmly confined to vascular complications. The unravelling of non-alcoholic fatty liver disease (NAFLD) as a serious complication of metabolic syndrome raises an important question: should we screen for NAFLD in Type 2 diabetes population? In a recent issue of Alimentary Pharmacology & Therapeutics, Doycheva et al. use magnetic resonance imaging-estimated proton density fat fraction to quantify liver fat and magnetic resonance elastography to detect advanced fibrosis in 100 individuals with Type 2 diabetes.1 The prevalence of NAFLD in this study was 65% and advanced fibrosis was observed in 7.1% of the study population. Extrapolating their findings to the current Type 2 diabetes population in the United States, the authors concluded that there are ~15.5 million individuals with NAFLD and ~1.8 million may have advanced fibrosis. The magnitude of the problem is considerable. Thus, the cost-benefit has to be considered particularly in screening for steatosis. Currently, there is no specific intervention that can be offered other than managing risk factors, which would have been addressed as part of the vascular complications prevention strategy. In contrast, screening for high-risk individuals with advanced fibrosis who might benefit from surveillance for cirrhotic complications and hepatocellular carcinoma seems intuitive. To this end, identifying the high-risk cohort based on risk factors and metabolic characteristics for non-invasive screening is crucial. In this study, Doycheva et al. demonstrates a positive association between age and advanced fibrosis. This observation underlines the future burden of NAFLD. In an ageing population, the majority of the 439 million individuals predicted to have diabetes by 2030 are likely to be over 60 years of age.2 Taken together, the observations in this study provide additional evidence in support of screening for NAFLD in Type 2 diabetes. Further studies focusing on risk stratifying are warranted. Declaration of personal and funding interests: None.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: